Costs of haematological disease high and rising-Reference-Cited by-同舟云学术

Costs of haematological disease high and rising

Published:2016-08 Issue:8 Volume:3 Page:e353-e354
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Green Tony,Bron Dominique,Chomienne Christine,de Wit Thom Duyvené,de Haas Fleur,Engert Andreas,Hagenbeek Anton,Jäger Ulrich,MacIntyre Elizabeth,Muckenthaler Martina U,Smand Carin,Sonneveld Pieter

Publisher

Elsevier BV

Subject

Hematology

Reference4 articles.

1. Economic burden of non-malignant blood disorders across Europe: a population-based cost study;Luengo-Fernandez;Lancet Haematol,2016

2. Economic burden of malignant blood disorders across Europe: a population-based cost analysis;Burns;Lancet Haematol,2016

3. The European Hematology Association Roadmap for European Haematology Research: a consensus document;Engert;Haematologica,2016

4. Blood disorders stepping into the limelight;Jäger;Haematologica,2016

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First-Line Treatment of Older Patients with CLL: A New Approach in the Chemo-Free Era;Cancers;2023-07-29

2. Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper;The Lancet Haematology;2022-10

3. Optimal Management of Chronic Lymphocytic Leukemia and Economic Constraints;The Cancer Journal;2021-07

4. Fair Pricing of Innovative Medicines: An EHA Position Paper;HemaSphere;2020-09-30

5. Assessment of Cancer Care Costs in Disease-Specific Cancer Care Pathways;International Journal of Environmental Research and Public Health;2020-07-02